R&D | Cutting-edge science and innovative research

R&D

Navigating geopolitical risks: Practical and legal mitigatio...

Geopolitical risk is now front of mind for many pharmaceutical leaders.

News

Flagship joins three biotechs together to form Etcelera

Flagship Pioneering has formed a new AI-focused biotech company, called Etcelera, by combining the platforms of three firms from its portfolio.

News

Dren Bio pockets $350m for rare blood cancer programme

Dren Bio has closed a sizeable private financing round, raising $350m for pivotal trials of a possible first-in-class therapy for rare blood cancers.

News

US gives $99m for Ebola jab project, as cases spread in Afri...

As Africa's CDC chief warns "unprecedented" Ebola outbreak could spread to other parts of the world, the US awards R&D funding to an IAVI vaccine.

News

Oura smart ring to be used in weight-loss outcomes trial

Oura has launched a trial to see if data collected from its smart rings can help scientists understand physiological changes with obesity treatment.

News

Abstract blue DNA background. Medicine concept. 3D Rendering

Biogen teams up with gene-editing startup Scribe on ALS prog...

Scribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 million deal with Biogen.

News

Lilly asks FDA for emergency clearance for COVID-19 antibody...

Eli Lilly has asked the FDA for an Emergency Use Authorization for its COVID-19 antibody therapy, after announcing new efficacy data from an ongoing trial.

News

"Tokyo, Japan - May 11, 2012: Pfizer building on May 11, 2012 in Tokyo. Pfizer is one of largest pharmaceutical companies worldwide with tremendous revenue $67.4 bn USD for 2011. It exists since 1849."

Race for COVID-19 vaccine hots up as EMA begins review of Bi...

The European Medicines Agency has begun a second “rolling review” of a potential coronavirus vaccine jointly developed by BioNTech and Pfizer, setting up a race with a rival from AstraZenec

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

R&D

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

Flagship joins three biotechs together to form Etcelera

Flagship Pioneering has formed a new AI-focused biotech company, called Etcelera, by combining the platforms of three firms from its portfolio.

News

Dren Bio pockets $350m for rare blood cancer programme

Dren Bio has closed a sizeable private financing round, raising $350m for pivotal trials of a possible first-in-class therapy for rare blood cancers.

Press Releases

Media Partner

PHARMAP 2027 Addresses the Future of Pharmaceutical Manufact...

Senior pharma professionals gather in Berlin on 19-20 April for the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2027

Press Releases

Partner Content

The Evolution Summit Announces September 2026 Program for Cl...

Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.

Views & Analysis

R&D

Navigating geopolitical risks: Practical and legal mitigatio...

Geopolitical risk is now front of mind for many pharmaceutical leaders.

R&D

Auto vacuum sealed vaccines in manufacturing plant

Reliability in life sciences logistics: What good looks like

What constitutes a reliable supply chain is changing rapidly.

R&D

Cardiovascular disease today: NMR-based lipoprotein profilin...

pharmaphorum spoke with Andreas Wolf, chief technology officer at numares Health about NMR-based lipoprotein profiling and cardiovascular disease.

Deep Dive

R&D

Cancer misinformation is a trust problem, not just an inform...

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

Podcasts

R&D

pharmaphorum podcast Episode 278, Shai Melcer, IIA

Bioconvergence & future human health, with Shai Melcer

Shai Melcer discusses bioconvergence, a multidisciplinary research and development approach that merges technologies.

R&D

pharmaphorum podcast Episode 272, Dr Harpreet Singh, Precision for Medicine

Understanding Operation Trialblazer, with Dr Harpreet Singh

Dr Harpreet Singh, CMO at Precision for Medicine, brings both an insider and outsider perspective to discussing Operation TRIALBLAZER.

R&D

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

Video

R&D

Boosting biotech in Basel – with Valentina Francia

pharmaphorum speaks with Valentina Francia from Basel Area Business and Innovation about why many life sciences startups are finding success in Basel.

R&D

Sponsored

Beyond recruitment: Creating patient engagement that lasts

In the final episode of our patient- and site-centric solutions interview series, Zoltan Varga discusses the importance of PRE.

R&D

LSX 2026 with Sam Possemiers, MRM Health

Taking the microbiome seriously, with Sam Possemiers

pharmaphorum catches up with MRM Health founder and CEO Sam Possemiers at LSX 2026.

White Papers

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.